Recombinant HVT Vectors for Multivalent Avian Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for poultry lack effectiveness in providing simultaneous protection against multiple avian pathogens, with live vaccines offering strong immunity but risking severe reactions and killed vaccines requiring multiple administrations and generating a weaker immune response.
Innovation Solution
Development of recombinant viral vectors, specifically using the Herpesvirus of Turkey (HVT) genome with inserted nucleotide sequences encoding antigens from multiple pathogens, such as Infectious Bursal Disease Virus, Newcastle Disease Virus, and others, to create multivalent vaccines that induce long-lasting immunity with reduced reaction risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If live vaccines are used to provide strong and long-lasting immunity, then immune response strength is improved, but risk of severe reactions increases
Solution Approach 1:
The patent uses a recombinant HVT vector as an intermediary carrier to deliver antigen genes. The HVT itself is non-pathogenic and safe, but it can express foreign antigens that trigger strong immune responses. This mediator approach allows the vaccine to provide strong immunity without the risks associated with live attenuated vaccines of the target pathogens.
Solution Approach 2:
The patent changes the pathogenicity parameter of the vaccine by using a non-pathogenic HVT strain instead of live attenuated strains of virulent pathogens. The HVT is genetically modified to express antigens from multiple pathogens, transforming it from a simple vaccine into a multivalent recombinant vector vaccine that maintains safety while inducing strong immunity.
2Reliability
If killed vaccines are used to ensure safety and stability, then safety is improved, but immune response strength decreases
Solution Approach 1:
The recombinant HVT acts as a mediator that combines the safety of killed vaccines with the immunogenicity of live vaccines. The HVT is non-pathogenic and stable like killed vaccines, but it replicates and expresses antigens in a way that generates strong and lasting immune responses similar to live vaccines.
Solution Approach 2:
The HVT vector is designed to perform multiple functions: it serves as a safe delivery vehicle, replicates in host cells to amplify antigen expression, presents multiple antigens simultaneously (multivalent), and induces both humoral and cellular immune responses. This multi-functionality allows a single vaccine to achieve outcomes previously requiring multiple separate vaccinations.
3Adaptability or versatility
If multiple separate vaccines are administered to protect against multiple pathogens, then protection coverage is improved, but number of administrations and complexity increase
Solution Approach 1:
The patent merges multiple antigen-encoding genes into a single HVT genome. The recombinant virus contains genes from different pathogens (e.g., MDV, IBV, NDV, IBDV) that are co-expressed during viral replication. This consolidation allows a single vaccination to provide protection against multiple pathogens that would otherwise require separate vaccines.
Solution Approach 2:
The HVT vector is designed as a universal platform that can accommodate multiple foreign antigen genes. It functions as a multivalent vaccine delivery system, capable of expressing antigens from different viral families simultaneously. This universality enables a single vaccine formulation to replace multiple separate vaccinations.
Data Source
AI summary
The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.